| Jul 4 |
HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status
|
| Jun 26 |
HUTCHMED to Announce 2024 Half-Year Financial Results
|
| Jun 24 |
Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024
|
| Jun 21 |
HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
|
| Jun 17 |
HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology
|
| Jun 7 |
HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China
|
| Jun 3 |
HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine
|
| May 24 |
HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting
|
